<DOC>
	<DOCNO>NCT01507077</DOCNO>
	<brief_summary>The purpose study ass Pharmacokinetics/Pharmacodynamics ( PK/PD ) , safety , effectiveness multiple subcutaneous dos Beloranib ( ZGN-440 ) .</brief_summary>
	<brief_title>ZGN-440 ( Beloranib Subcutaneous Injection ) Treatment Obesity</brief_title>
	<detailed_description>This protocol design test safety efficacy drug call Beloranib ( ZGN-440 ) . It test ability reduce weight obese female subject non-childbearing potential . The study provide information much ZGN-440 get blood , long stay body , affect biological marker .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<criteria>Obese otherwise healthy female Nonchildbearing potential ( surgically sterile , postmenopausal , receive implant injectable contraceptive least 3 month ) BMI ≥ 30 ≤ 45 kg/m2 Stable body weight past 2 month Use weight loss agent past month History eat disorder History type 1 type 2 diabetes mellitus Current smoker</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Obese</keyword>
	<keyword>Obesity</keyword>
	<keyword>Overweight</keyword>
</DOC>